-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Ebola GP investigational vaccine
Paused developmental vaccine candidates
Therapeutic area | Infectious disease | Status | Technology |
---|---|---|---|
Parasitic diseases | Ebola | Phase 1 | Matrix-M™ adjuvant |
Therapeutic area
Parasitic diseases
Infectious disease
Ebola
Status
Phase 1
Technology
Matrix-M™ adjuvant
About the candidate
Our Ebola glycoprotein (GP) investigational vaccine is expressed in insect cells using our core recombinant baculovirus technology. The investigational vaccine works in concert with the Matrix-M™ adjuvant to enhance the magnitude of the immune response.
Why it matters
Ebola virus (EBOV) causes a rare but serious illness that can have devastating consequences on a community. With a fatality rate of up to 90%,1 it is critical to develop effective vaccines to help control the spread of EBOV outbreaks.
- Ebola virus disease. WHO. Available at:https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease [Accessed 3 Sept 2021].